Kringle Pharma reports February exercise

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on March 2, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Kringle Pharma reports February exercise status of 16th warrant issue

Source disclosure: March 02, 2026, 10:00 JST Kringle Pharma,Inc. [4884.T] TOKYO, Mar 02 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) reported the monthly exercise status of its 16th warrant issue (exercise price adjustment clause attached) allocated to EVO FUND for February 2026. In February, 416 warrants were exercised daily, totaling 416 warrants exercised throughout the month. As of the end of January 31, 2026, there were 1,244,000 shares outstanding, including treasury sha